PHIL in the Treatment of Intracranial dAVF.
Trial ID or NCT#
Status
Purpose
This study is a prospective, multicenter, single-arm study. Patients with Dural Arteriovenous Fistulas (dAVF) have a few choice for safe treatment. In this study, all patients with qualifying dAVFs will be treated with PHIL® Liquid Embolic material.
Official Title
PHIL dAVF: Study of PHIL® Embolic System In The Treatment of Intracranial Dural Arteriovenous Fistulas
Eligibility Criteria
- - Age 22 - 80 years. - Subject is willing and capable of complying with all study protocol requirements, including specified follow-up period. - Subject or authorized legal representative must provide written informed consent prior to initiation of any study procedures. - Subject has an intracranial dAVF
- - Subject having multiple dAVFs to be treated. - Subject with a history of life threatening allergy to contrast media (unless treatment for allergy is tolerated). - Subject has known allergies to dimethylsulfoxide, iodine. - Subject is currently participating in another clinical study - Female subject is currently pregnant. - Subject has co-morbid conditions that may limit survival to less than 24 months.
Investigator(s)
View on ClinicalTrials.gov